Raymond B. Penn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raymond B. Penn has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Deepak A. Deshpande
Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Center for Translational Medicine, Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, PA 19107, USA
9 shared publications- Ajay P. Nayak
Center for Translational Medicine, Department of Medicine, and Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University , Philadelphia, PA
6 shared publications - Deepak A. Deshpande
Center for Translational Medicine, Jane and Leonard Korman Lung Center Thomas Jefferson University Philadelphia Pennsylvania USA
6 shared publications Tonio Pera
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Center for Translational Medicine, Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, PA, United States
6 shared publicationsReynold A. Panettieri
Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, New Jersey
5 shared publicationsAjay P. Nayak
Center for Translational Medicine, Jane and Leonard Korman Lung Institute, Division of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania
4 shared publications
Latest Publications
- 8 July 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (9) , 1157-1159
Oxidized phosphatidylcholines extend their reach: from airway dysfunction to bronchodilator dysfunction
- 8 July 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (9) , 1157-1159
Oxidized phosphatidylcholines extend their reach: from airway dysfunction to bronchodilator dysfunction
- Open Access
- 7 June 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (17) , 5315-5335
Agonist‐specific conformational dynamics at the β 2 ‐adrenoceptor dictate allosteric modulation of Gαs signalling and bronchodilation
Background and Purpose: β 2 ‐adrenoceptor (β 2 AR) agonists are the cornerstone of asthma therapy and promote bronchodilation through Gαs signalling in airway smooth muscle (ASM), but their efficacy is limited by β‐arrestin‐mediated β 2 AR desensitization. We recently described allosteric modulators (AMs) of β 2 AR that preferentially enhance isoproterenol‐mediated β 2 AR‐Gαs signalling in ASM. Orthosteric β‐agonists differ in efficacy, kinetics and signalling bias, and how this diversity shapes allosteric modulation of β 2 ARs remains unclear. We investigated whether AMs could selectively modulate β 2 AR‐Gαs signalling and bronchodilation in response to endogenous and clinically relevant β‐agonists. Experimental Approach: The effects of a positive AM (PAM37) and two negative AMs (NAM36 and NAM42) were examined on β‐agonist‐induced Gαs and β‐arrestin recruitment and downstream signalling (cAMP, PKA and ERK) in HEK293 cells expressing β 2 ARs and primary human ASM cells. Bronchodilation was assessed using murine precision‐cut lung slices and in vivo lung mechanics. Molecular dynamics (MD) simulations were performed to delineate structural determinants of agonist‐dependent AM activity. Key Results: PAM37 enhanced, whereas NAMs attenuated β 2 AR‐Gαs coupling, signalling and bronchodilation with no effect on β‐arrestin‐ERK signalling, establishing Gαs signalling and functional bias. AM effects differed in magnitude and kinetic profiles across β‐agonists, with fenoterol uniquely resistant to modulation. MD simulations revealed that fenoterol stabilizes a quasi‐inactive β 2 AR conformation characterized by an TM6 shift that occludes the allosteric pocket, providing a structural basis for its resistance. Conclusions and Implications: These findings establish orthosteric ligand‐dependent allostery as a fundamental feature of β 2 AR pharmacology. PAM37 represents a tool to selectively enhance bronchodilation by β‐agonists in asthma.
- 7 June 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (17) , 5315-5335
Open AccessAgonist‐specific conformational dynamics at the β 2 ‐adrenoceptor dictate allosteric modulation of Gαs signalling and bronchodilation
Background and Purpose: β 2 ‐adrenoceptor (β 2 AR) agonists are the cornerstone of asthma therapy and promote bronchodilation through Gαs signalling in airway smooth muscle (ASM), but their efficacy is limited by β‐arrestin‐mediated β 2 AR desensitization. We recently described allosteric modulators (AMs) of β 2 AR that preferentially enhance isoproterenol‐mediated β 2 AR‐Gαs signalling in ASM. Orthosteric β‐agonists differ in efficacy, kinetics and signalling bias, and how this diversity shapes allosteric modulation of β 2 ARs remains unclear. We investigated whether AMs could selectively modulate β 2 AR‐Gαs signalling and bronchodilation in response to endogenous and clinically relevant β‐agonists. Experimental Approach: The effects of a positive AM (PAM37) and two negative AMs (NAM36 and NAM42) were examined on β‐agonist‐induced Gαs and β‐arrestin recruitment and downstream signalling (cAMP, PKA and ERK) in HEK293 cells expressing β 2 ARs and primary human ASM cells. Bronchodilation was assessed using murine precision‐cut lung slices and in vivo lung mechanics. Molecular dynamics (MD) simulations were performed to delineate structural determinants of agonist‐dependent AM activity. Key Results: PAM37 enhanced, whereas NAMs attenuated β 2 AR‐Gαs coupling, signalling and bronchodilation with no effect on β‐arrestin‐ERK signalling, establishing Gαs signalling and functional bias. AM effects differed in magnitude and kinetic profiles across β‐agonists, with fenoterol uniquely resistant to modulation. MD simulations revealed that fenoterol stabilizes a quasi‐inactive β 2 AR conformation characterized by an TM6 shift that occludes the allosteric pocket, providing a structural basis for its resistance. Conclusions and Implications: These findings establish orthosteric ligand‐dependent allostery as a fundamental feature of β 2 AR pharmacology. PAM37 represents a tool to selectively enhance bronchodilation by β‐agonists in asthma.
- Open Access
- 1 May 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Qualitative beta-2-adrenoceptor signaling in the regulation of human airway epithelia mucin and cytokine production
Background: Numerous in vivo studies have demonstrated beta-2-adrenoceptor (β 2 AR) -agonism as permissive in the development of allergic lung inflammation, and have implicated the arrestin-dependent signaling arm of the β 2 AR in mediating this effect. However, the specific cell type(s) mediating β 2 AR regulation of allergic lung inflammation remain unestablished. Methods: To explore the potential contribution of airway epithelia in this phenomenon, we compared the ability of ractopamine (RP), recently identified as a Gs-biased beta-agonist, to that of the unbiased/balanced beta-agonist albuterol (ALB), on IL-13-stimulated mucin and cytokine production in human airway epithelia cultures in air–liquid interface (HAE). Results: ALB, which activates both the β 2 AR-arrestin and -Gs signaling pathways significantly augmented IL-13-induced mucin production in HAE. RP, which preferentially signals via Gs/PKA, did not. Although IL-13 stimulated production of numerous cytokines, including IL-1α, IL-1RA, MDC, TGF-α, and GROα, ALB-mediated augmentation of these cytokines was highly variable and not statistically significant. Similarly, RP did not augment the induction of cytokines stimulated by IL-13. Moreover, in contrast to previous studies that reported a requirement of concomitant β 2 AR agonism for IL-13 to stimulate cytokine production, such a requirement was observed only in minority of the (12) cultures examined. Conclusions: These data implicate arrestin-dependent β 2 AR signaling augmenting airway epithelial mucin production as a contributor to the previously-demonstrated pro-inflammatory effects of β 2 AR agonism in vivo. Moreover, they suggest that beta-agonist effects on the cytokine profile in the allergen-inflamed lung may be influenced by specific asthmatic endotypes and involve cooperativity among multiple cell types.
- 1 May 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessQualitative beta-2-adrenoceptor signaling in the regulation of human airway epithelia mucin and cytokine production
Background: Numerous in vivo studies have demonstrated beta-2-adrenoceptor (β 2 AR) -agonism as permissive in the development of allergic lung inflammation, and have implicated the arrestin-dependent signaling arm of the β 2 AR in mediating this effect. However, the specific cell type(s) mediating β 2 AR regulation of allergic lung inflammation remain unestablished. Methods: To explore the potential contribution of airway epithelia in this phenomenon, we compared the ability of ractopamine (RP), recently identified as a Gs-biased beta-agonist, to that of the unbiased/balanced beta-agonist albuterol (ALB), on IL-13-stimulated mucin and cytokine production in human airway epithelia cultures in air–liquid interface (HAE). Results: ALB, which activates both the β 2 AR-arrestin and -Gs signaling pathways significantly augmented IL-13-induced mucin production in HAE. RP, which preferentially signals via Gs/PKA, did not. Although IL-13 stimulated production of numerous cytokines, including IL-1α, IL-1RA, MDC, TGF-α, and GROα, ALB-mediated augmentation of these cytokines was highly variable and not statistically significant. Similarly, RP did not augment the induction of cytokines stimulated by IL-13. Moreover, in contrast to previous studies that reported a requirement of concomitant β 2 AR agonism for IL-13 to stimulate cytokine production, such a requirement was observed only in minority of the (12) cultures examined. Conclusions: These data implicate arrestin-dependent β 2 AR signaling augmenting airway epithelial mucin production as a contributor to the previously-demonstrated pro-inflammatory effects of β 2 AR agonism in vivo. Moreover, they suggest that beta-agonist effects on the cytokine profile in the allergen-inflamed lung may be influenced by specific asthmatic endotypes and involve cooperativity among multiple cell types.
- Open Access
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 72 (5) , 466-468
Channeling Relaxation through Multiple Means: TMEM16A Antagonism for Asthma
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 72 (5) , 466-468
Open AccessChanneling Relaxation through Multiple Means: TMEM16A Antagonism for Asthma
- 1 February 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 72 (2) , 133-144
A-Kinase–Anchoring Protein Subtypes Differentially Regulate GPCR Signaling and Function in Human Airway Smooth Muscle
AKAPs (A-kinase–anchoring proteins) act as scaffold proteins that anchor the regulatory subunits of the cAMP-dependent PKA (protein kinase A) to coordinate and compartmentalize signaling elements and signals downstream of Gs-coupled GPCRs (G protein–coupled receptors). The β2AR (β-2-adrenoceptor), as well as the Gs-coupled EP2 and EP4 (E-prostanoid) receptor subtypes of the EP receptor subfamily, are effective regulators of multiple airway smooth muscle (ASM) cell functions whose dysregulation contributes to asthma pathobiology. Here, we identify specific roles of the AKAPs Ezrin and Gravin in differentially regulating PKA substrates downstream of the β2AR, EP2R (EP2 receptor) and EP4R. Knockdown of Ezrin, Gravin, or both in primary human ASM cells caused differential phosphorylation of the PKA substrates VASP (vasodilator-stimulated phosphoprotein) and HSP20 (heat shock protein 20). Ezrin knockdown, as well as combined Ezrin and Gravin knockdown, significantly reduced the induction of phospho-VASP and phospho-HSP20 by β2AR, EP2R, and EP4R agonists. Gravin knockdown inhibited the induction of phospho-HSP20 by β2AR, EP2R, and EP4R agonists. Knockdown of Ezrin, Gravin, or both also attenuated histamine-induced phosphorylation of MLC20. Moreover, knockdown of Ezrin, Gravin, or both suppressed the inhibitory effects of Gs-coupled receptor agonists on cell migration in ASM cells. These findings demonstrate the role of AKAPs in regulating Gs-coupled GPCR signaling and function in ASM and suggest the therapeutic utility of targeting specific AKAP family members in the management of asthma.
- 1 February 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 72 (2) , 133-144
A-Kinase–Anchoring Protein Subtypes Differentially Regulate GPCR Signaling and Function in Human Airway Smooth Muscle
AKAPs (A-kinase–anchoring proteins) act as scaffold proteins that anchor the regulatory subunits of the cAMP-dependent PKA (protein kinase A) to coordinate and compartmentalize signaling elements and signals downstream of Gs-coupled GPCRs (G protein–coupled receptors). The β2AR (β-2-adrenoceptor), as well as the Gs-coupled EP2 and EP4 (E-prostanoid) receptor subtypes of the EP receptor subfamily, are effective regulators of multiple airway smooth muscle (ASM) cell functions whose dysregulation contributes to asthma pathobiology. Here, we identify specific roles of the AKAPs Ezrin and Gravin in differentially regulating PKA substrates downstream of the β2AR, EP2R (EP2 receptor) and EP4R. Knockdown of Ezrin, Gravin, or both in primary human ASM cells caused differential phosphorylation of the PKA substrates VASP (vasodilator-stimulated phosphoprotein) and HSP20 (heat shock protein 20). Ezrin knockdown, as well as combined Ezrin and Gravin knockdown, significantly reduced the induction of phospho-VASP and phospho-HSP20 by β2AR, EP2R, and EP4R agonists. Gravin knockdown inhibited the induction of phospho-HSP20 by β2AR, EP2R, and EP4R agonists. Knockdown of Ezrin, Gravin, or both also attenuated histamine-induced phosphorylation of MLC20. Moreover, knockdown of Ezrin, Gravin, or both suppressed the inhibitory effects of Gs-coupled receptor agonists on cell migration in ASM cells. These findings demonstrate the role of AKAPs in regulating Gs-coupled GPCR signaling and function in ASM and suggest the therapeutic utility of targeting specific AKAP family members in the management of asthma.
- Open Access
- 22 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23842
Molecular mechanism of bitter taste receptor agonist‐mediated relaxation of airway smooth muscle
G‐protein‐coupled receptors (GPCRs) belonging to the type 2 taste receptors (TAS2Rs) family are predominantly present in taste cells to allow the perception of bitter‐tasting compounds. TAS2Rs have also been shown to be expressed in human airway smooth muscle (ASM), and TAS2R agonists relax ASM cells and bronchodilate airways despite elevating intracellular calcium. This calcium “paradox” (calcium mediates contraction by pro‐contractile Gq‐coupled GPCRs) and the mechanisms by which TAS2R agonists relax ASM remain poorly understood. To gain insight into pro‐relaxant mechanisms effected by TAS2Rs, we employed an unbiased phosphoproteomic approach involving dual‐mass spectrometry to determine differences in the phosphorylation of contractile‐related proteins in ASM following the stimulation of cells with TAS2R agonists, histamine (an agonist of the Gq‐coupled H1 histamine receptor) or isoproterenol (an agonist of the Gs‐coupled β 2 ‐adrenoceptor) alone or in combination. Our study identified differential phosphorylation of proteins regulating contraction, including A‐kinase anchoring protein (AKAP)2, AKAP12, and RhoA guanine nucleotide exchange factor (ARHGEF)12. Subsequent signaling analyses revealed RhoA and the T853 residue on myosin light chain phosphatase (MYPT)1 as points of mechanistic divergence between TAS2R and Gs‐coupled GPCR pathways. Unlike Gs‐coupled receptor signaling, which inhibits histamine‐induced myosin light chain (MLC)20 phosphorylation via protein kinase A (PKA)‐dependent inhibition of intracellular calcium mobilization, HSP20 and ERK1/2 activity, TAS2Rs are shown to inhibit histamine‐induced pMLC20 via inhibition of RhoA activity and MYPT1 phosphorylation at the T853 residue. These findings provide insight into the TAS2R signaling in ASM by defining a distinct signaling mechanism modulating inhibition of pMLC20 to relax contracted ASM.
- 22 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23842
Open AccessMolecular mechanism of bitter taste receptor agonist‐mediated relaxation of airway smooth muscle
G‐protein‐coupled receptors (GPCRs) belonging to the type 2 taste receptors (TAS2Rs) family are predominantly present in taste cells to allow the perception of bitter‐tasting compounds. TAS2Rs have also been shown to be expressed in human airway smooth muscle (ASM), and TAS2R agonists relax ASM cells and bronchodilate airways despite elevating intracellular calcium. This calcium “paradox” (calcium mediates contraction by pro‐contractile Gq‐coupled GPCRs) and the mechanisms by which TAS2R agonists relax ASM remain poorly understood. To gain insight into pro‐relaxant mechanisms effected by TAS2Rs, we employed an unbiased phosphoproteomic approach involving dual‐mass spectrometry to determine differences in the phosphorylation of contractile‐related proteins in ASM following the stimulation of cells with TAS2R agonists, histamine (an agonist of the Gq‐coupled H1 histamine receptor) or isoproterenol (an agonist of the Gs‐coupled β 2 ‐adrenoceptor) alone or in combination. Our study identified differential phosphorylation of proteins regulating contraction, including A‐kinase anchoring protein (AKAP)2, AKAP12, and RhoA guanine nucleotide exchange factor (ARHGEF)12. Subsequent signaling analyses revealed RhoA and the T853 residue on myosin light chain phosphatase (MYPT)1 as points of mechanistic divergence between TAS2R and Gs‐coupled GPCR pathways. Unlike Gs‐coupled receptor signaling, which inhibits histamine‐induced myosin light chain (MLC)20 phosphorylation via protein kinase A (PKA)‐dependent inhibition of intracellular calcium mobilization, HSP20 and ERK1/2 activity, TAS2Rs are shown to inhibit histamine‐induced pMLC20 via inhibition of RhoA activity and MYPT1 phosphorylation at the T853 residue. These findings provide insight into the TAS2R signaling in ASM by defining a distinct signaling mechanism modulating inhibition of pMLC20 to relax contracted ASM.
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 69 (6) , 605-607
Reactive Oxygen Species Behaving Badly: Oxidized Phosphatidylcholines Corrupt Ca2+ Signaling in Airway Smooth Muscle
- 1 December 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 69 (6) , 605-607
Open AccessReactive Oxygen Species Behaving Badly: Oxidized Phosphatidylcholines Corrupt Ca2+ Signaling in Airway Smooth Muscle
- 1 November 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 69 (5) , 584-591
Prorelaxant E-type Prostanoid Receptors Functionally Partition to Different Procontractile Receptors in Airway Smooth Muscle
Prostaglandin E2 imparts diverse physiological effects on multiple airway cells through its actions on four distinct E-type prostanoid (EP) receptor subtypes (EP1–EP4). Gs-coupled EP2 and EP4 receptors are expressed on airway smooth muscle (ASM), yet their capacity to regulate the ASM contractile state remains subject to debate. We used EP2 and EP4 subtype-specific agonists (ONO-259 and ONO-329, respectively) in cell- and tissue-based models of human ASM contraction—magnetic twisting cytometry (MTC), and precision-cut lung slices (PCLSs), respectively—to study the EP2 and EP4 regulation of ASM contraction and signaling under conditions of histamine or methacholine (MCh) stimulation. ONO-329 was superior (<0.05) to ONO-259 in relaxing MCh-contracted PCLSs (log half maximal effective concentration [logEC50]: 4.9 × 10−7 vs. 2.2 × 10−6; maximal bronchodilation ± SE, 35 ± 2% vs. 15 ± 2%). However, ONO-259 and ONO-329 were similarly efficacious in relaxing histamine-contracted PCLSs. Similar differential effects were observed in MTC studies. Signaling analyses revealed only modest differences in ONO-329– and ONO-259–induced phosphorylation of the protein kinase A substrates VASP and HSP20, with concomitant stimulation with MCh or histamine. Conversely, ONO-259 failed to inhibit MCh-induced phosphorylation of the regulatory myosin light chain (pMLC20) and the F-actin/G-actin ratio (F/G-actin ratio) while effectively inhibiting their induction by histamine. ONO-329 was effective in reversing induced pMLC20 and the F/G-actin ratio with both MCh and histamine. Thus, the contractile-agonist–dependent differential effects are not explained by changes in the global levels of phosphorylated protein kinase A substrates but are reflected in the regulation of pMLC20 (cross-bridge cycling) and F/G-actin ratio (actin cytoskeleton integrity, force transmission), implicating a role for compartmentalized signaling involving muscarinic, histamine, and EP receptor subtypes.
- 1 November 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 69 (5) , 584-591
Prorelaxant E-type Prostanoid Receptors Functionally Partition to Different Procontractile Receptors in Airway Smooth Muscle
Prostaglandin E2 imparts diverse physiological effects on multiple airway cells through its actions on four distinct E-type prostanoid (EP) receptor subtypes (EP1–EP4). Gs-coupled EP2 and EP4 receptors are expressed on airway smooth muscle (ASM), yet their capacity to regulate the ASM contractile state remains subject to debate. We used EP2 and EP4 subtype-specific agonists (ONO-259 and ONO-329, respectively) in cell- and tissue-based models of human ASM contraction—magnetic twisting cytometry (MTC), and precision-cut lung slices (PCLSs), respectively—to study the EP2 and EP4 regulation of ASM contraction and signaling under conditions of histamine or methacholine (MCh) stimulation. ONO-329 was superior (<0.05) to ONO-259 in relaxing MCh-contracted PCLSs (log half maximal effective concentration [logEC50]: 4.9 × 10−7 vs. 2.2 × 10−6; maximal bronchodilation ± SE, 35 ± 2% vs. 15 ± 2%). However, ONO-259 and ONO-329 were similarly efficacious in relaxing histamine-contracted PCLSs. Similar differential effects were observed in MTC studies. Signaling analyses revealed only modest differences in ONO-329– and ONO-259–induced phosphorylation of the protein kinase A substrates VASP and HSP20, with concomitant stimulation with MCh or histamine. Conversely, ONO-259 failed to inhibit MCh-induced phosphorylation of the regulatory myosin light chain (pMLC20) and the F-actin/G-actin ratio (F/G-actin ratio) while effectively inhibiting their induction by histamine. ONO-329 was effective in reversing induced pMLC20 and the F/G-actin ratio with both MCh and histamine. Thus, the contractile-agonist–dependent differential effects are not explained by changes in the global levels of phosphorylated protein kinase A substrates but are reflected in the regulation of pMLC20 (cross-bridge cycling) and F/G-actin ratio (actin cytoskeleton integrity, force transmission), implicating a role for compartmentalized signaling involving muscarinic, histamine, and EP receptor subtypes.
- Open Access
- 1 September 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (10) , 105209
The biased M3 mAChR ligand PD 102807 mediates qualitatively distinct signaling to regulate airway smooth muscle phenotype
- 1 September 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (10) , 105209
Open AccessThe biased M3 mAChR ligand PD 102807 mediates qualitatively distinct signaling to regulate airway smooth muscle phenotype